Small molecule · Inhibitor of Tyrosine-protein phosphatase non-receptor type 11 (SHP2) (PTPN11) · developed by Erasca
ERAS-601 is an orally bioavailable inhibitor of the SHP2 phosphatase (PTPN11) that binds SHP2 and blocks its activity, suppressing MAPK signaling in SHP2-dependent tumor cells. It is being studied in advanced or metastatic solid tumors.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT04866134 | Phase 1/2 | Advanced or Metastatic Solid Tumors | Completed | ERAS |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Advanced or Metastatic Solid Tumors
Updated Nov 15, 2026. Something wrong or missing? Report it on the ERAS page.
See ERAS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
ERAS catalysts and pipeline →